

COMPANY ANNOUNCEMENT

The following is a company announcement issued by the Company, in terms of the rules of Prospects MTF, a market regulated as a multi-lateral trading facility and operated by the Malta Stock Exchange (“Prospects”).

Results of Meeting of Bondholders

QUOTE

Further to company announcement PHC55 issued by the Company on the 20th December 2022, the Company is hereby announcing that pursuant to a bondholders meeting held today, the 4th January 2023, the required majority of holders of the €5,000,000 5.75% unsecured bonds 2025-2028 (ISIN: MT0002011204) issued by the Company (the “**Maturing Bondholders**”), in accordance with sub-section 17.15 of the company admission document, dated 17th October 2018 (the “**2018 Company Admission Document**”), approved the early redemption of the €5,000,000 5.75% unsecured bonds 2025-2028 (ISIN: MT0002011204) (the “**Maturing Bonds**”) issued by the Company and admitted to listing and trading on the Prospects MTF List of the Malta Stock Exchange pursuant to the 2018 Company Admission Document.

As already communicated through the company announcement PHC54 issued on 15th December 2022, the Company has obtained regulatory approval for the issue of €17,000,000 6% Unsecured Bonds redeemable in 2033, to be issued at par with a nominal value of €100 per bond (the “**New Bonds**”), pursuant to the terms and conditions set out in a prospectus dated 5th December 2022 (the “**Prospectus**”).

In terms of the Prospectus, the Company will be granting preference to Maturing Bondholders for the subscription to the New Bonds. Application forms for the subscription of the New Bonds shall be mailed to the Maturing Bondholders as from today, 4th January 2023.

Full details of the issue of the New Bonds are included in the Prospectus which is available on the Company’s website (www.pharmacarefinance.com).

The Company undertakes to keep the public and its stakeholders informed on the next steps related to the redemption of the Maturing Bonds and the subscription and issue of the New Bonds.

UNQUOTE



Dr Katia Cachia
Company Secretary

REFERENCE PHC56
4th January 2023